|
?:abstract
|
-
The disease caused by coronavirus SARS-CoV-2, named CoViD-19, has become a global emergency Physicians that treat patients with COVID-19 face new and unexpected challenges every day COVID-19 can lead to systemic coagulation activation and thrombotic complications Recent studies confirmed very high cumulative incidence of thromboembolic events, particularly in critically ill patients with COVID-19 pneumonia The sepsis-related activation of the coagulation combined with high prevalence of common thrombotic risk factors can contribute to this prothrombotic state Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Coagulation biomarkers, including D-dimer, can help in the identification of patients with the risk of complications and mortality D-dimers may be used to monitor the effectiveness of anticoagulants, although this practice is not universally accepted Risk assessment in admission is important to identify high-risk patients with multiple risk factors before the onset of the viral infection (Caprini score >8) In case of sepsis-induced coagulopathy, anticoagulant therapy appears to be associated with better prognosis in relation to mortality In this review, we summarize available epidemiological data on venous thromboembolism and recommendations on thromboprophylaxis in COVID-19 Future research should focus on optimal diagnostic and prophylactic strategies to prevent VTE and potentially improve survival © 2020, Professionalnye Izdaniya All rights reserved
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}